Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 9:44 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 385–408 of 2,353 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Positron emission tomography Clear all

Conditions: CIC-Rearranged Sarcoma, Metastatic Ewing Sarcoma, Metastatic High Grade Sarcoma, Metastatic Undifferentiated Round Cell Sarcoma, Metastatic Undifferentiated Sarcoma, Not Otherwise Specified, Round Cell Sarcoma With EWSR1-non-ETS Fusion, Sarcoma With BCOR Genetic Alterations
Interventions: Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Cyclophosphamide, Doxorubicin Hydrochloride, Echocardiography Test, Etoposide, Fludeoxyglucose F-18, Ifosfamide, Irinotecan Hydrochloride, Magnetic Resonance Imaging, Positron Emission Tomography, Questionnaire Administration, Radiation Therapy, Regorafenib, Surgical Procedure, Vincristine Sulfate; Procedure · Drug · Other + 1 more
Lead sponsor: Children's Oncology Group; Network
Eligibility: 12 Years to 50 Years
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 8
States / cities: Birmingham, Alabama • Honolulu, Hawaii • Chicago, Illinois + 5 more

Conditions: Adult Glioblastoma, Depression, Recurrent Adult Brain Tumor
Interventions: vorinostat, temozolomide, magnetic resonance spectroscopic imaging, survey administration; Drug · Procedure · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Cancer
Interventions: Bone scan, 99mTc-methyl diphosphonate, Positron Emission Tomography (PET) scan, 18F-Fludeoxyglucose (18F-FDG), Computed Tomography (CT) scan, 18F-Sodium Fluoride (18F-NaF), Whole Body Magnetic Resonance Imaging (WB-MRI) scan, Gadopentetate dimeglumine, Gadofosveset, Gadobutrol; Procedure · Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 114 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2019
U.S. locations: 1
States / cities: Stanford, California

Conditions: Prostate Cancer
Interventions: flotufolastat F 18, Relugolix 120 MG, Serum PSA and Testosterone; Diagnostic Test · Drug
Lead sponsor: Urology Clinics of North Texas; Network
Eligibility: Male only
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: AL Amyloidosis
Interventions: Autologous Hematopoietic Stem Cell Transplantation, Biopsy, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Bortezomib, Computed Tomography, Cyclophosphamide, Daratumumab and Hyaluronidase-fihj, Dexamethasone, Echocardiography, Magnetic Resonance Imaging, Melphalan, Positron Emission Tomography, Stem Cell Isolation, Survey Administration; Procedure · Drug · Other
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: 18 Years and older
Enrollment: 338 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 117
States / cities: Goodyear, Arizona • Tucson, Arizona • Duarte, California + 93 more

Conditions: Prostate Cancer (Adenocarcinoma), Adenocarcinoma of the Prostate, Metastatic Castration-resistant Prostate Cancer (mCRPC), Metastatic Hormone-Sensitive Prostate Cancer (mHSPC), Biochemical Recurrence (BCR), High-Risk Localized Prostate Cancer
Interventions: RYZ711, PSMA PET/CT; Drug · Diagnostic Test
Lead sponsor: RayzeBio, Inc.; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 116 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Migraine, Chronic Migraine
Interventions: Not listed
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years to 65 Years
Enrollment: 78 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2015
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Carotid Atherosclerosis
Interventions: Cu[64]-25%-CANF-Comb PET-MR; Device
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 21 Years and older
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2021
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Glioblastoma
Interventions: Radiologic exams; Other
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Breast Cancer
Interventions: Positron Emission Tomography (PET), Fluorine-18 labeled 1-amino-3-fluorocyclobutane-1-carboxylic acid (FACBC), Positron emission mammography (PEM) When available, MR; Procedure · Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 21 Years and older · Female only
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 1
States / cities: New York, New York

Conditions: Healthy, Serotonin Transporter
Interventions: Not listed
Lead sponsor: National Institute of Mental Health (NIMH); NIH
Eligibility: Not listed
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003 – 2005
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Neoplasms
Interventions: PET Scan, EF5, Carbogen, Dichloroacetate; Procedure · Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 1
States / cities: Stanford, California

Conditions: Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms
Interventions: [18F]-ML-10 in conjunction with PET imaging; Other
Lead sponsor: Aposense Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2010
U.S. locations: 4
States / cities: Boston, Massachusetts • Teaneck, New Jersey • New York, New York + 1 more

Conditions: Alcohol Use Disorder
Interventions: [C-11], Pittsburgh Compound B; Radiation · Drug
Lead sponsor: University of Pittsburgh; Other
Eligibility: 40 Years to 65 Years
Enrollment: 39 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Eosinophilic Esophagitis
Interventions: Computerized Tomography scan, Single Photon Emission Computed Tomography scans, Technetium Tc 99M, Planar Images, Esophagogastroduodenoscopy; Radiation · Drug · Procedure
Lead sponsor: University of Utah; Other
Eligibility: 18 Years to 70 Years
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Hepatocellular Carcinoma
Interventions: F18-FDG, MRI, CT, F18-DCFPyL, Tumor biopsy; Drug · Device · Procedure
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Clinical Stage IV Gastric Cancer AJCC v8, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Metastatic Gastric Carcinoma, Metastatic Malignant Neoplasm in the Peritoneum
Interventions: Aldesleukin, Biopsy Procedure, Biospecimen Collection, Computed Tomography, Diagnostic Laparoscopy, Fluorouracil, Leucovorin Calcium, Magnetic Resonance Imaging, Nivolumab, Oxaliplatin, Positron Emission Tomography; Biological · Procedure · Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Recurrent Adult Soft Tissue Sarcoma, Stage I Adult Soft Tissue Sarcoma, Stage II Adult Soft Tissue Sarcoma, Stage III Adult Soft Tissue Sarcoma, Stage IV Adult Soft Tissue Sarcoma
Interventions: fludeoxyglucose F 18, 18F-fluoromisonidazole, positron emission tomography, computed tomography, laboratory biomarker analysis; Radiation · Other · Procedure
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 2
States / cities: Seattle, Washington

Conditions: Coronary Artery Disease
Interventions: Ga-68 Galmydar; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years to 99 Years
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Recurrent Non-Small Cell Lung Carcinoma, Stage IB Non-Small Cell Lung Carcinoma, Stage IIA Non-Small Cell Lung Carcinoma, Stage IIB Non-Small Cell Lung Carcinoma, Stage IIIA Non-Small Cell Lung Cancer, Stage IV Non-Small Cell Lung Cancer
Interventions: Cisplatin, CT, Docetaxel, FDG, FLT, PET/CT, Surgery; Drug · Procedure
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 19 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 2
States / cities: Baltimore, Maryland • Columbus, Ohio

Conditions: Lung Cancer
Interventions: Real-time Position Management system, Discovery ST multislice PET/CT scanner, Infinia Hawkeye SPECT/CT gamma camera, Pinnacle3 treatment planning system, SKYLight nuclear camera, DTPA, TECHNETIUM TC 99M MAA; Device · Drug
Lead sponsor: Billy W. Loo Jr.; Other
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 1
States / cities: Stanford, California

Conditions: Cognitive Dysfunction
Interventions: GE-287, Vizamyl; Drug
Lead sponsor: GE Healthcare; Industry
Eligibility: 50 Years to 110 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 6
States / cities: Aventura, Florida • Merritt Island, Florida • Miami, Florida + 2 more

Conditions: Mantle Cell Lymphoma
Interventions: Autologous Hematopoietic Stem Cell Transplantation, Biospecimen Collection, Bone Marrow Aspirate, Bone Marrow Biopsy, Computed Tomography, Positron Emission Tomography, Rituximab, Rituximab and Hyaluronidase Human; Procedure · Biological
Lead sponsor: ECOG-ACRIN Cancer Research Group; Network
Eligibility: 18 Years to 70 Years
Enrollment: 689 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2027
U.S. locations: 374
States / cities: Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 236 more

Conditions: Diffuse Large B-cell Lymphoma, Follicle Center Lymphoma
Interventions: Zevalin, Y-90-Zevalin, Rituximab, In-111 Zevalin; Drug
Lead sponsor: Spectrum Pharmaceuticals, Inc; Industry
Eligibility: 60 Years and older
Enrollment: 79 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 28
States / cities: Casa Grande, Arizona • Berkeley, California • Duarte, California + 24 more

Search by objective public record fields.

Testing a New Combination of Anti-cancer Drugs in Patients Newly Diagnosed With Ewing Sarcoma Who Have Cancer That Has Spread to Other Parts of the Body

Magnetic Resonance Spectroscopy Imaging in Predicting Response to Vorinostat and Temozolomide in Patients With Recurrent or Progressive Glioblastoma

Combined 18F-NaF/18F-FDG PET/MRI for Detection of Skeletal Metastases

Pilot Study: Androgen Deprivation Therapy Impact on PSMA-PET Sensitivity in Prostatectomy Staging

Comparing Dara-VCD Chemotherapy Plus Stem Cell Transplant to Dara-VCD Chemotherapy Alone for People Who Have Newly Diagnosed AL Amyloidosis

RYZ711 Diagnostic Platform Study

Neuroimaging Studies of Chronic Primary Headaches Using Positron Emission Tomography and Magnetic Resonance Imaging

PET Imaging of Natriuretic Peptide Receptor C (NPR-C) in Carotid Atherosclerosis

Evaluating Tumor Pseudoprogression With FLT-PET and MRI

FACBC PET and PEM as a Staging Tool and Indicator of Therapeutic Response in Breast Cancer Patients

Brain Imaging of Serotonin Transporters in the Brain

Imaging and Biomarkers of Hypoxia in Solid Tumors

An Efficacy and Safety Study to Assess [18F]-ML-10 in Detecting Response of Tumors to Chemotherapy and Radiation

[C-11]PiB PET Imaging in Alcohol Use Disorders

Radiation Dose in Humans From Orally Administered Tc99m-Heparin

18F-DCFPyL PET/CT in Hepatocellular Carcinoma

Aldesleukin With Nivolumab and Standard Chemotherapy for Treatment of Gastric Cancer With Peritoneal Metastasis

18F-Fluoromisonidazole and Fludeoxyglucose F 18 PET/CT Patients With Soft Tissue Sarcoma

Development and Translation of Generator-Produced PET Tracer for Myocardial Perfusion Imaging-Dosimetry Group

A Comparison of FLT to FDG PET/CT in the Early Assessment of Chemotherapy Response in Stage IB-IIIA Resectable NSCLC

4D-CT-based Ventilation Imaging for Adaptive Functional Guidance in Radiotherapy

Flutemetamol F 18 Injection Formulation Comparison

Rituximab With or Without Stem Cell Transplant in Treating Patients With Minimal Residual Disease-Negative Mantle Cell Lymphoma in First Complete Remission

Study of Zevalin Versus Observation in Participants at Least 60 Years Old With Newly Diagnosed Diffuse Large B-cell Lymphoma in Positron Emission Tomography (PET)-Negative Complete Remission After Rituximab-Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) or R-CHOP-like Therapy